Commerzbank Aktiengesellschaft FI Has $22.61 Million Stake in Stryker Corporation (NYSE:SYK)

Commerzbank Aktiengesellschaft FI increased its holdings in shares of Stryker Corporation (NYSE:SYK - Free Report) by 2,166.4% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 60,739 shares of the medical technology company's stock after acquiring an additional 58,059 shares during the period. Commerzbank Aktiengesellschaft FI's holdings in Stryker were worth $22,610,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Elefante Mark B bought a new stake in Stryker during the 4th quarter worth approximately $337,000. Mogy Joel R Investment Counsel Inc. grew its position in Stryker by 3.4% during the 1st quarter. Mogy Joel R Investment Counsel Inc. now owns 98,216 shares of the medical technology company's stock worth $36,561,000 after acquiring an additional 3,218 shares during the last quarter. Ferguson Wellman Capital Management Inc. grew its position in Stryker by 1.9% during the 1st quarter. Ferguson Wellman Capital Management Inc. now owns 174,871 shares of the medical technology company's stock worth $65,096,000 after acquiring an additional 3,341 shares during the last quarter. Harbor Capital Advisors Inc. bought a new stake in Stryker during the 1st quarter worth approximately $1,840,000. Finally, Mar Vista Investment Partners LLC grew its position in Stryker by 10.2% during the 1st quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company's stock worth $33,572,000 after acquiring an additional 8,353 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the sale, the director owned 3,417,326 shares of the company's stock, valued at approximately $1,288,195,208.96. This trade represents a 5.53% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 5.90% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on SYK. Citigroup reaffirmed a "buy" rating and set a $455.00 price objective (up previously from $443.00) on shares of Stryker in a report on Thursday, May 22nd. Roth Mkm upped their price objective on Stryker from $405.00 to $456.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. BTIG Research reaffirmed a "buy" rating on shares of Stryker in a report on Monday. Truist Financial upped their price objective on Stryker from $390.00 to $400.00 and gave the stock a "hold" rating in a report on Monday, May 5th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $442.00 price objective on shares of Stryker in a report on Friday, March 21st. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. Based on data from MarketBeat, Stryker currently has an average rating of "Moderate Buy" and an average price target of $428.55.

Stryker Trading Down 0.5%

Stryker stock traded down $1.85 during mid-day trading on Thursday, hitting $389.02. 1,039,855 shares of the company's stock were exchanged, compared to its average volume of 1,352,593. The firm has a market capitalization of $148.49 billion, a P/E ratio of 52.57, a PEG ratio of 2.95 and a beta of 0.91. Stryker Corporation has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The company has a quick ratio of 1.00, a current ratio of 1.64 and a debt-to-equity ratio of 0.69. The company's 50 day simple moving average is $385.38 and its 200-day simple moving average is $377.55.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping the consensus estimate of $2.73 by $0.11. The business had revenue of $5.87 billion for the quarter, compared to the consensus estimate of $5.68 billion. Stryker had a return on equity of 23.74% and a net margin of 12.31%. The firm's revenue was up 11.9% compared to the same quarter last year. During the same quarter last year, the business posted $2.50 EPS. On average, equities analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.86%. The ex-dividend date is Monday, June 30th. Stryker's payout ratio is presently 45.41%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.